
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio Inc is positioned favorably due to its innovative pipeline targeting serious immune-related diseases, with GRI-0621 showing promising interim data that suggests positive impacts on fibrogenesis and lung function. The company's current valuation appears attractive, with a notable upside potential based on NPV analysis, indicating the stock may offer substantial returns relative to its current price. Additionally, the recent positive interim biomarker data further supports the company's growth prospects and underscores the strength of its therapeutic candidates in addressing significant unmet medical needs.
Bears say
GRI Bio Inc. has reported significant net losses, with a loss of $3.4 million translating to an EPS of $(1.28), which was worse than both internal estimates and consensus forecasts. Furthermore, the company’s second reported net loss of $3.9 million and an EPS of $(7.72) again fell short of expectations, indicating persistent financial challenges. Despite potential growth opportunities, the company faces substantial risks that include liquidity issues, the viability of its product candidates in clinical trials, regulatory approval hurdles, and competitive pressures, leading to a cautious financial outlook.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares